UBS Group
LIMNW

UBS Group’s Liminatus Pharma Warrants LIMNW Stock Holding History

UBS Group’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180 Buy
4,507
+295
+7% +$19 ﹤0.01% 10048
2025
Q4 		$147 Buy
4,212
+3,922
+1,352% +$396 ﹤0.01% 10146
2025
Q3 		$43 Sell
290
-1,730
-86% -$338 ﹤0.01% 10041
2025
Q2 		$485 Buy
+2,020
New +$397 ﹤0.01% 9814

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group's LIMNW Position: Q1 2026 in Review

UBS Group increased its Liminatus Pharma Warrants (LIMNW) stake by 7% in Q1 2026, buying an estimated $19 and bringing the position to 4,507 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #10048.

UBS Group first reported a position in LIMNW in Q2 2025 and has held it in 4 quarters since. The position peaked at $485 in Q2 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • UBS Group held 4,507 shares of Liminatus Pharma Warrants worth $180 as of Q1 2026.
  • UBS Group bought 295 Liminatus Pharma Warrants shares in Q1 2026, an estimated $19.
  • Liminatus Pharma Warrants made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10048 holding.
  • UBS Group first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 4 quarters since.
  • UBS Group's Liminatus Pharma Warrants position peaked at $485 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.